Boger DL - Search Results

1

Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems.

Fedorova I, Hashimoto A, Fecik RA, Hedrick MP, Hanus LO, Boger DL, Rice KC, Basile AS. Fedorova I, et al. Among authors: boger dl. J Pharmacol Exp Ther. 2001 Oct;299(1):332-42. J Pharmacol Exp Ther. 2001. PMID: 11561096

2

Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.

Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF. Boger DL, et al. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5044-9. doi: 10.1073/pnas.97.10.5044. Proc Natl Acad Sci U S A. 2000. PMID: 10805767 Free PMC article.

3

alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution.

Boger DL, Miyauchi H, Hedrick MP. Boger DL, et al. Bioorg Med Chem Lett. 2001 Jun 18;11(12):1517-20. doi: 10.1016/s0960-894x(01)00211-6. Bioorg Med Chem Lett. 2001. PMID: 11412972

4

Fatty acid amide hydrolase substrate specificity.

Boger DL, Fecik RA, Patterson JE, Miyauchi H, Patricelli MP, Cravatt BF. Boger DL, et al. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2613-6. doi: 10.1016/s0960-894x(00)00528-x. Bioorg Med Chem Lett. 2000. PMID: 11128635

5

Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.

Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CR, Jorgensen WL, Cravatt BF. Boger DL, et al. J Med Chem. 2005 Mar 24;48(6):1849-56. doi: 10.1021/jm049614v. J Med Chem. 2005. PMID: 15771430 Free PMC article.

6

A new class of highly cytotoxic diketopiperazines.

Boger DL, Fink BE, Hedrick MP. Boger DL, et al. Bioorg Med Chem Lett. 2000 May 15;10(10):1019-20. doi: 10.1016/s0960-894x(00)00152-9. Bioorg Med Chem Lett. 2000. PMID: 10843206

7

Substituent effects within the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065.

Boger DL, Stauffer F, Hedrick MP. Boger DL, et al. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2021-4. doi: 10.1016/s0960-894x(01)00372-9. Bioorg Med Chem Lett. 2001. PMID: 11454471

8

Synthesis, chemical properties, and biological evaluation of CC-1065 and duocarmycin analogues incorporating the 5-methoxycarbonyl-1,2,9,9a-tetrahydrocyclopropa.

Boger DL, Hughes TV, Hedrick MP. Boger DL, et al. J Org Chem. 2001 Apr 6;66(7):2207-16. doi: 10.1021/jo001772g. J Org Chem. 2001. PMID: 11281757

9

Total synthesis of ningalin B utilizing a heterocyclic azadiene Diels-Alder reaction and discovery of a new class of potent multidrug resistant (MDR) reversal agents.

Boger DL, Soenen DR, Boyce CW, Hedrick MP, Jin Q. Boger DL, et al. J Org Chem. 2000 Apr 21;65(8):2479-83. doi: 10.1021/jo9916535. J Org Chem. 2000. PMID: 10789460

10

Parallel synthesis and evaluation of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogues of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain.

Boger DL, Schmitt HW, Fink BE, Hedrick MP. Boger DL, et al. J Org Chem. 2001 Oct 5;66(20):6654-61. doi: 10.1021/jo010454u. J Org Chem. 2001. PMID: 11578217

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

361 results

Search Page